Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,023Revenue $M1.1Net Margin (%)-880.1Z-Score37.9
Enterprise Value $M956EPS $-1.2Operating Margin %-1,081.3F-Score5
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-1,080.1Higher ROA y-yY
Price/Book14.710-y EBITDA Growth Rate %0Quick Ratio10.9Cash flow > EarningsY
Price/Sales2855-y EBITDA Growth Rate %0Current Ratio10.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-40.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-48.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M28.0ROI % (ttm)-59.8Gross Margin Increase y-yN

Gurus Latest Trades with NLNK

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NLNKJean-Marie Eveillard 2014-03-31 Add0.02%$21.38 - $50.4
($33.68)
$ 36.599%Add 28.35%1,161,805
NLNKJean-Marie Eveillard 2013-09-30 Add0.01%$15.78 - $20.08
($17.83)
$ 36.59105%Add 21.32%778,354
NLNKJean-Marie Eveillard 2013-06-30 Add0.02%$11.27 - $22.56
($15.73)
$ 36.59133%Add 95.04%641,554
NLNKJean-Marie Eveillard 2013-03-31 Buy 0.01%$11.4 - $12.7
($12.08)
$ 36.59203%New holding, 328939 sh.328,939
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NLNK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NLNK - CALLJean-Marie Eveillard 2014-09-3011,7600.040.02
NLNK Jean-Marie Eveillard 2014-09-301,257,6194.50.07-3.78%
Premium Most recent portfolio changes are included for Premium Members only!


NLNK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ramsey William J.Quality Assurance Officer 2015-01-23Sell2,500$40-8.52view
Link Charles J. Jr.Chairman of the Board and CEO 2015-01-07Sell20,000$37.99-3.69view
Wiley BrianVP of Business Development 2015-01-02Sell20,000$40.33-9.27view
Link Charles J. Jr.Chairman of the Board and CEO 2014-12-04Sell20,000$37.84-3.3view
HENNEMAN JOHN B IIIEVP, CFO 2014-11-25Buy5,000$34.356.52view
Link Charles J. Jr.Chairman of the Board and CEO 2014-11-10Sell20,000$32.9411.08view
LINK GORDON H JRCFO 2014-10-24Sell2,500$40.39-9.41view
Link Charles J. Jr.Chairman of the Board and CEO 2014-10-22Sell25,000$40.26-9.12view
Ramsey William J.Quality Assurance Officer 2014-10-22Sell10,000$40-8.52view
Ramsey William J.Quality Assurance Officer 2014-10-16Sell5,000$3021.97view

Press Releases about NLNK :

    Quarterly/Annual Reports about NLNK:

    News about NLNK:

    Articles On GuruFocus.com
    NewLink Genetics Corporation Offers a Risky Way to Generate Income Sep 11 2013 
    Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 


    More From Other Websites
    TrovaGene Partners with Leading Cancer Research Institutes - Analyst Blog Jan 26 2015
    First GSK Ebola vaccine shipment due to arrive in Liberia Jan 23 2015
    Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst Blog Jan 22 2015
    NewLink Genetics to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 07 2015
    NewLink Genetics to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 07 2015
    NEWLINK GENETICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 06 2015
    J&J, Bavarian Nordic start clinical tests in Ebola vaccine race Jan 06 2015
    J&J, Bavarian Nordic start clinical tests in Ebola vaccine race Jan 06 2015
    J&J and Bavarian Nordic start clinical tests of Ebola vaccine Jan 06 2015
    J&J and Bavarian Nordic start clinical tests of Ebola vaccine Jan 06 2015
    Merck-NewLink Ebola vaccine trial resumes at lower dose -Geneva hospital Jan 05 2015
    Are Placebos Ethical In Ebola Trials? Dec 30 2014
    Ebola crisis could last through 2015 as marks year since outbreak-expert-TRFN Dec 24 2014
    NewLink Genetics Surges 3% Following Ebola Contract News Dec 22 2014
    NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30... Dec 22 2014
    HTML PDF Dec 22 2014
    NEWLINK GENETICS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 22 2014
    NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30... Dec 22 2014
    Human trial of experimental Merck Ebola vaccine is suspended Dec 11 2014
    Ebola vaccine trial halted temporarily after joint pains -Geneva hospital Dec 11 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK